Daidzein from Dietary Supplement to a Drug Candidate: An Evaluation of Potential
Mohammed Ubaid, Salauddin, Md Andalib Shadani, S.M. Kawish, Mohammed Albratty, Hafiz A. Makeen, Hassan A. Alhazmi, Asim Najmi, Khalid Zoghebi, Maryam A Halawi, Abuzer Ali, Md Shamsher Alam, Zeenat Iqbal, Mohd. Aamir Mirza
Abstract
Daidzein (DDZ) is a well-known nutraceutical supplement belonging to the class of isoflavones. It is isolated from various sources such as alfalfa, soybean, and red clover. It demonstrates a broad array of pharmacological/beneficial properties such as cardiovascular exercise, cholesterol reduction, and anticancer, antifibrotic, and antidiabetic effects, which make it effective in treating a wide range of diseases. Its structure and operation are the same as those of human estrogens, which are important in preventing osteoporosis, cancer, and postmenopausal diseases. It is thus a promising candidate for development as a phytopharmaceutical. Addressing safety, efficacy, and physicochemical properties are the primary prerequisites. DDZ is already ingested every day in varying amounts, so there should not be a significant safety risk; however, each indication requires a different dose to be determined. Some clinical trials are already being conducted globally to confirm its safety, efficacy, and therapeutic potential. Furthermore, as a result of its therapeutic influence on health, in order to establish intellectual property, patents are utilized. In light of the vast potential of eugenol, this review presents a detailed data collection on DDZ to substantiate the claim to develop it in the therapeutic category.